BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Gastric cancer AND CALR, ENSG00000179218, 811, P27797, SSA, RO, FLJ26680, cC1qR AND Treatment
107 results:

  • 1. Personalized treatment of well-differentiated gastric neuroendocrine tumors based on clinicopathological classification and grading: A multicenter retrospective study.
    Huang J; Liu H; Yang D; Xu T; Wang J; Li J
    Chin Med J (Engl); 2024 Mar; 137(6):720-728. PubMed ID: 38384175
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Value of
    Miao Y; Feng R; Yu T; Guo R; Zhang M; Wang Y; Hai W; Shangguan C; Zhu Z; Li B
    J Nucl Med; 2024 Feb; 65(2):213-220. PubMed ID: 38164574
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Clinical impact of unsuccessful subcutaneous administration of octreotide LAR instead of intramuscular administration in patients with metastatic gastroenteropancreatic neuroendocrine tumors.
    Krishnan T; Safro M; Furlanetto DM; Gill S; Solar Vasconcelos JP; Stuart HC; Martineau P; Loree JM
    J Neuroendocrinol; 2024 Jan; 36(1):e13360. PubMed ID: 38088132
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trial.
    Janjigian YY; Kawazoe A; Bai Y; Xu J; Lonardi S; Metges JP; Yanez P; Wyrwicz LS; Shen L; Ostapenko Y; Bilici M; Chung HC; Shitara K; Qin SK; Van Cutsem E; Tabernero J; Li K; Shih CS; Bhagia P; Rha SY;
    Lancet; 2023 Dec; 402(10418):2197-2208. PubMed ID: 37871604
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. The potential effect and mechanism of Saikosaponin A against gastric cancer.
    Wang C; Zhang R; Chen X; Yuan M; Wu J; Sun Q; Miao C; Jing Y
    BMC Complement Med Ther; 2023 Aug; 23(1):295. PubMed ID: 37608281
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Gastro-Enteric-Pancreatic Neuroendocrine Tumor treatment:
    Sanli Y; Denizmen D; Subramaniam RM
    PET Clin; 2023 Apr; 18(2):201-214. PubMed ID: 36858745
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. What have we learnt from the past - would treatment decisions for GEP-NET patients differ between 2012 to 2016 by the new recommendations in 2022?
    Stiefel R; Lehmann K; Winder T; Siebenhüner AR
    BMC Cancer; 2023 Feb; 23(1):148. PubMed ID: 36782152
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Somatostatin-analog effect on pancreatic fistula after radical gastrectomy: a pilot randomized controlled trial.
    Sha S; Qiao W; Feng R; Lian G; Chen Y; Peng L; Wang J; Li L; Tian F; Jing C
    J Cancer Res Clin Oncol; 2023 Aug; 149(9):6329-6339. PubMed ID: 36745222
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Recent progress and current challenges of immunotherapy in advanced/metastatic esophagogastric adenocarcinoma.
    Moehler M; Högner A; Wagner AD; Obermannova R; Alsina M; Thuss-Patience P; van Laarhoven H; Smyth E
    Eur J Cancer; 2022 Nov; 176():13-29. PubMed ID: 36183651
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Factors, Including Clinical Trial Eligibility, Associated with Induction of Third-Line treatment for Advanced gastric cancer.
    Ando T; Hosokawa A; Sakumura M; Motoo I; Kajiura S; Hirano K; Miwa T; Yokota T; Nakada N; Ueda Y; Ueda A; Tsukada K; Ogawa K; Nakaya A; Teramoto A; Nanjo S; Mihara H; Fujinami H; Fujii T; Yasuda I
    Oncology; 2023; 101(1):59-68. PubMed ID: 36103845
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. The role of infections in the causation of cancer in Kenya.
    Tuei VC; Maiyoh GK; Ndombera FT
    Cancer Causes Control; 2022 Dec; 33(12):1391-1400. PubMed ID: 36087193
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Targeting the complexity of ERBB2 biology in gastroesophageal carcinoma.
    Augustin JE; Soussan P; Bass AJ
    Ann Oncol; 2022 Nov; 33(11):1134-1148. PubMed ID: 35963482
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. Systemic Therapy of Advanced Well-differentiated Small Bowel Neuroendocrine Tumors Progressive on Somatostatin Analogues.
    Agarwal P; Mohamed A
    Curr Treat Options Oncol; 2022 Sep; 23(9):1233-1246. PubMed ID: 35939200
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. A Nomogram Combining Neutrophil-to-Lymphocyte Ratio and D-Dimer Predicts Chemosensitivity of Oxaliplatin-Based First-Line Chemotherapy in Patients with Unresectable Advanced gastric cancer.
    Shen H; Wu S; Su R; Chen Y; He Y
    Technol Cancer Res Treat; 2022; 21():15330338221112741. PubMed ID: 35880288
    [No Abstract]    [Full Text] [Related]  

  • 15. A phase 1b study of andecaliximab in combination with S-1 plus platinum in Japanese patients with gastric adenocarcinoma.
    Ooki A; Satoh T; Muro K; Takashima A; Kadowaki S; Sakai D; Ichimura T; Mitani S; Kudo T; Chin K; Kitano S; Thai D; Zavodovskaya M; Liu J; Boku N; Yamaguchi K
    Sci Rep; 2022 Jun; 12(1):11007. PubMed ID: 35773363
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. Sex and gender disparities in patients with advanced gastroesophageal adenocarcinoma: data from the AGAMENON-SEOM registry.
    Plazas JG; Arias-Martinez A; Lecumberri A; Martínez de Castro E; Custodio A; Cano JM; Hernandez R; Montes AF; Macias I; Pieras-Lopez A; Diez M; Visa L; Tocino RV; Lago NM; Limón ML; Gil M; Pimentel P; Mangas M; Granja M; Carnicero AM; Pérez CH; Gonzalez LG; Jimenez-Fonseca P; Carmona-Bayonas A
    ESMO Open; 2022 Jun; 7(3):100514. PubMed ID: 35714478
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. Real-world comparison of healthcare resource utilization and costs of [
    Cox T; O'Connell M; Leeuwenkamp O; Palimaka S; Reed N
    Curr Med Res Opin; 2022 Aug; 38(8):1305-1317. PubMed ID: 35418254
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. Immunotherapy in gastric cancer.
    Högner A; Moehler M
    Curr Oncol; 2022 Mar; 29(3):1559-1574. PubMed ID: 35323331
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. Quality performance indicators for the surgical treatment of gastric adenocarcinoma: a systematic review.
    Kulasegaran S; Woodhouse B; MacCormick AD; Srinivasa S; Koea J
    ANZ J Surg; 2022 Sep; 92(9):1995-2002. PubMed ID: 35238137
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. Comparing Somatostatin Analogs in the treatment of Advanced Gastroenteropancreatic Neuroendocrine Tumors.
    Allaw MB; Switchenko JM; Khalil L; Wu C; Alese OB; Akce M; Draper A; Jones AT; El-Rayes B; Shaib W
    Oncology; 2022; 100(3):131-139. PubMed ID: 35078191
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 6.